JP2018534304A5 - - Google Patents

Download PDF

Info

Publication number
JP2018534304A5
JP2018534304A5 JP2018524713A JP2018524713A JP2018534304A5 JP 2018534304 A5 JP2018534304 A5 JP 2018534304A5 JP 2018524713 A JP2018524713 A JP 2018524713A JP 2018524713 A JP2018524713 A JP 2018524713A JP 2018534304 A5 JP2018534304 A5 JP 2018534304A5
Authority
JP
Japan
Prior art keywords
adjuvant
composition
poly
lipid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018524713A
Other languages
English (en)
Japanese (ja)
Other versions
JP6989134B2 (ja
JP2018534304A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2016/051324 external-priority patent/WO2017083963A1/en
Publication of JP2018534304A publication Critical patent/JP2018534304A/ja
Publication of JP2018534304A5 publication Critical patent/JP2018534304A5/ja
Priority to JP2021128886A priority Critical patent/JP2021181462A/ja
Application granted granted Critical
Publication of JP6989134B2 publication Critical patent/JP6989134B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018524713A 2015-11-18 2016-11-15 ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物 Expired - Fee Related JP6989134B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021128886A JP2021181462A (ja) 2015-11-18 2021-08-05 ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562256875P 2015-11-18 2015-11-18
US62/256,875 2015-11-18
PCT/CA2016/051324 WO2017083963A1 (en) 2015-11-18 2016-11-15 Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021128886A Division JP2021181462A (ja) 2015-11-18 2021-08-05 ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物

Publications (3)

Publication Number Publication Date
JP2018534304A JP2018534304A (ja) 2018-11-22
JP2018534304A5 true JP2018534304A5 (https=) 2019-10-31
JP6989134B2 JP6989134B2 (ja) 2022-01-05

Family

ID=58717143

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018524713A Expired - Fee Related JP6989134B2 (ja) 2015-11-18 2016-11-15 ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物
JP2021128886A Pending JP2021181462A (ja) 2015-11-18 2021-08-05 ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021128886A Pending JP2021181462A (ja) 2015-11-18 2021-08-05 ポリi:cポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物

Country Status (7)

Country Link
US (2) US11160861B2 (https=)
EP (1) EP3377099A4 (https=)
JP (2) JP6989134B2 (https=)
CN (1) CN108430505A (https=)
AU (1) AU2016355926A1 (https=)
CA (1) CA3005127C (https=)
WO (1) WO2017083963A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018509384A (ja) 2015-01-06 2018-04-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. リピドa模倣体、調製方法、及びその使用
EP3377099A4 (en) * 2015-11-18 2019-07-24 ImmunoVaccine Technologies Inc. ADJUVANT SYSTEMS AND WATER-FREE VAPOR COMPOSITION OF ONE POLYI: C-POLYNUCLEOTIDADJUVANS AND ADJUVANS ON LIPID BASE
WO2018151816A1 (en) * 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
CN111093623A (zh) * 2017-07-10 2020-05-01 免疫疫苗技术公司 药物组合物、使用限定大小的脂质囊泡颗粒的制备方法及其用途
KR102098097B1 (ko) * 2017-08-16 2020-05-26 주식회사 차백신연구소 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
CN111565706A (zh) * 2017-11-09 2020-08-21 免疫疫苗技术公司 药物组合物、包括脂质囊泡颗粒尺寸设定的制备方法及其用途
KR20210086612A (ko) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 펩타이드 백신
KR102292147B1 (ko) * 2020-11-18 2021-08-23 주식회사 차백신연구소 경구용 항바이러스제 및 리포펩타이드와 폴리(i:c) 아쥬반트를 포함한 치료백신을 유효성분으로 포함하는 만성 b형 간염의 예방 또는 치료용 약제학적 조성물, 약제학적 병용제제, 병용제 키트
MX2023009417A (es) * 2021-02-16 2023-12-01 Vaccitech North America Inc Nanopartículas de autoensamblaje basadas en péptidos anfifílicos.
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強
JPWO2023145755A1 (https=) 2022-01-25 2023-08-03
WO2024092352A1 (en) * 2022-11-04 2024-05-10 Immunovaccine Technologies Inc. Compositions that recruit and activate antigen presenting cells
KR20250141137A (ko) * 2022-12-08 2025-09-26 토마스 제퍼슨 유니버시티 다당류 백신용 면역 아주반트
WO2024186646A1 (en) * 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making lipid adjuvanted compositions
WO2024186623A1 (en) * 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making dried pharmaceutical compositions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US6245523B1 (en) 1996-11-20 2001-06-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
CA2203843C (en) 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
EP1333858B8 (en) 2000-11-07 2006-06-14 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
AU2002219711B8 (en) 2000-12-08 2006-03-02 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
CN103143004A (zh) 2005-02-04 2013-06-12 萨瓦克公司 存活蛋白肽疫苗
EP1850832B1 (en) 2005-02-07 2014-12-31 Lipotek PTY Ltd Adjuvanting material
BRPI0607605A2 (pt) 2005-02-08 2009-09-15 Queensland Inst Med Res moléculas imunogênicas
DE602006021408D1 (de) 2005-04-27 2011-06-01 Univ Leiden Medical Ct Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
CN101765607B (zh) 2007-05-31 2015-09-09 莱顿教学医院 侵润宫颈恶性肿瘤的t细胞所靶向的用于疫苗的hpv表位
ES2482192T3 (es) 2007-05-31 2014-08-01 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Vacunación intradérmica del péptido de HPV
CA2700808C (en) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
CN101815529B (zh) * 2007-10-03 2016-03-09 免疫疫苗技术有限公司 包含抗原、两性化合物和疏水载体的组合物及其应用
KR100900837B1 (ko) * 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
WO2009118356A2 (en) 2008-03-25 2009-10-01 Formac Pharmaceuticals N.V. Preparation method for solid disupersions
ES2524699T3 (es) 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
WO2010123365A1 (en) 2009-04-24 2010-10-28 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Increasing the immunogenicity of epithelial cells infected with human papilloma virus (hpv)
GB201019240D0 (en) 2010-11-15 2010-12-29 Vib Vzw Respiratory syncytical virus vaccine
JP6240077B2 (ja) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
US10022441B2 (en) * 2013-03-27 2018-07-17 Immunovaccine Technologies, Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
KR101501583B1 (ko) * 2013-03-29 2015-03-12 주식회사 차백신연구소 리포펩티드 및 폴리(i:c)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물
EP3377099A4 (en) * 2015-11-18 2019-07-24 ImmunoVaccine Technologies Inc. ADJUVANT SYSTEMS AND WATER-FREE VAPOR COMPOSITION OF ONE POLYI: C-POLYNUCLEOTIDADJUVANS AND ADJUVANS ON LIPID BASE

Similar Documents

Publication Publication Date Title
JP2018534304A5 (https=)
Diaz-Arévalo et al. Nanoparticle-based vaccines: opportunities and limitations
Tan et al. Outer membrane vesicles: current status and future direction of these novel vaccine adjuvants
US11077184B2 (en) Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response
Wang et al. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies
Woodrow et al. Mucosal vaccine design and delivery
Huang et al. Research progress on emulsion vaccine adjuvants
Xu et al. Intranasal DNA vaccine for protection against respiratory infectious diseases: the delivery perspectives
Kaurav et al. Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage
JP2014528955A5 (https=)
Liu et al. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice
Korsholm et al. Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status
JP7409594B2 (ja) 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用
Carneiro et al. Protective effect of antigen delivery using monoolein-based liposomes in experimental hematogenously disseminated candidiasis
Xiang et al. Promising particle-based vaccines in cancer therapy
Soni et al. The sixth revolution in pediatric vaccinology: immunoengineering and delivery systems
US20200054571A1 (en) Formulation for protection through controlled release of microparticles containing recombinant outer membrane vesicles
Bo et al. Materials‐based vaccines for infectious diseases
Temchura et al. Immunogenicity of Recombinant Lipid-Based Nanoparticle Vaccines: Danger Signal vs. Helping Hand
Gandhapudi et al. Recombinant Protein Vaccines Formulated with Enantio-Specific Cationic Lipid R-DOTAP Induce Protective Cellular and Antibody-Mediated Immune Responses in Mice. Viruses. 2023; 15 (2): 432
Barik et al. Nanotechnology-Based Vaccination for TB
Noureddine et al. Nanoparticle Vaccines for Immunotherapy: From Design to Clinical Trials
Caetano et al. Chitosan-alginate microparticulate delivery system for an alternative route of administration of BCG vaccine
Balar et al. Antigen Selection and Design
Becker Vaccine technologies & the rationale for new nanoparticle formulations